0 287

Cited 2 times in

Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization

DC Field Value Language
dc.contributor.author김경민-
dc.contributor.author김도영-
dc.contributor.author윤미진-
dc.contributor.author황상현-
dc.contributor.author이혜원-
dc.contributor.author김동우-
dc.date.accessioned2022-12-22T02:20:48Z-
dc.date.available2022-12-22T02:20:48Z-
dc.date.issued2022-06-
dc.identifier.issn0363-9762-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/191538-
dc.description.abstractPurpose: This study aimed to evaluate the prognostic value of metabolic parameters on 18F-FDG PET/CT and tumor dose (TD) on posttreatment 90Y PET/CT in patients with hepatocellular carcinoma (HCC) who underwent 90Y transarterial radioembolization (TARE). Patients and methods: Forty-seven HCC patients treated with 90Y TARE were retrospectively enrolled between January 2013 and October 2018. 18F-FDG PET/CT was performed before treatment. Maximum tumor SUV-to-mean normal liver SUV ratio (TLR), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured for each patient. Voxel dosimetry was performed on 90Y PET/CT images to measure TD. The prognostic significance of metabolic parameters on 18F-FDG PET/CT, TD on 90Y PET/CT, and clinical factors for overall survival (OS) was evaluated. In addition, TD on 90Y PET/CT was analyzed in relation to the administered dose of 90Y-labeled microspheres and metabolic parameters on 18F-FDG PET/CT. Results: The median patient age was 57 years, and 37 patients (78.7%) were men. During the follow-up period, 25 patients (53.2%) died. In univariable analysis, Barcelona Clinic Liver Cancer stage C, Child-Pugh score, TD on 90Y PET/CT, TLR, MTV, and TLG were significant prognostic factors affecting OS (P < 0.05). In multivariable analysis, Barcelona Clinic Liver Cancer stage C and high TLG on 18F-FDG PET/CT were independent prognostic factors for OS (P < 0.05). The 1-year OS rates were 72.9% in patients with low TLG and 33.3% in patients with high TLG (P < 0.05). We also found that TD on 90Y PET/CT was not correlated with the administered dose of 90Y-labeled microspheres, but negatively correlated with TLG on pretreatment 18F-FDG PET/CT (P < 0.05). Conclusions: TLG, a parameter incorporating both the degree of 18F-FDG uptake and amount of metabolically active tumor volume on pretreatment 18F-FDG PET/CT, is a better prognostic factor than TD on 90Y PET/CT for predicting OS in HCC patients treated with 90Y TARE.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherLippincott-
dc.relation.isPartOfCLINICAL NUCLEAR MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCarcinoma, Hepatocellular* / diagnostic imaging-
dc.subject.MESHCarcinoma, Hepatocellular* / metabolism-
dc.subject.MESHFemale-
dc.subject.MESHFluorodeoxyglucose F18 / metabolism-
dc.subject.MESHGlycolysis-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms* / diagnostic imaging-
dc.subject.MESHLiver Neoplasms* / metabolism-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPositron Emission Tomography Computed Tomography-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTumor Burden-
dc.subject.MESHYttrium Radioisotopes / therapeutic use-
dc.titleTotal Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiology (영상의학교실)-
dc.contributor.googleauthorSang Hyun Hwang-
dc.contributor.googleauthorHye-Suk Hong-
dc.contributor.googleauthorDongwoo Kim-
dc.contributor.googleauthorGyoung Min Kim-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorMisu Lee-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorMi-Ae Park-
dc.contributor.googleauthorMijin Yun-
dc.identifier.doi10.1097/RLU.0000000000004128-
dc.contributor.localIdA00296-
dc.contributor.localIdA00385-
dc.contributor.localIdA02550-
dc.contributor.localIdA05953-
dc.contributor.localIdA03318-
dc.relation.journalcodeJ00595-
dc.identifier.eissn1536-0229-
dc.identifier.pmid35384891-
dc.identifier.urlhttps://journals.lww.com/nuclearmed/Fulltext/2022/06000/Total_Lesion_Glycolysis_on_18F_FDG_PET_CT_Is_a.26.aspx-
dc.contributor.alternativeNameKim, Gyoung Min-
dc.contributor.affiliatedAuthor김경민-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor윤미진-
dc.contributor.affiliatedAuthor황상현-
dc.contributor.affiliatedAuthor이혜원-
dc.citation.volume47-
dc.citation.number6-
dc.citation.startPageE437-
dc.citation.endPageE443-
dc.identifier.bibliographicCitationCLINICAL NUCLEAR MEDICINE, Vol.47(6) : E437-E443, 2022-06-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.